The Scientific Basis for Chelation: Animal Studies and Lead Chelation
Open Access
- 12 October 2013
- journal article
- review article
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 9 (4) , 326-338
Abstract
This presentation summarizes several of the rodent and non-human studies that we have conducted to help inform the efficacy and clinical utility of succimer (meso-2,3-dimercaptosuccincinic acid) chelation treatment. We address the following questions: (1) What is the extent of body lead, and in particular brain lead reduction with chelation, and do reductions in blood lead accurately reflect reductions in brain lead? (2) Can succimer treatment alleviate the neurobehavioral impacts of lead poisoning? And (3) does succimer treatment, in the absence of lead poisoning, produce neurobehavioral deficits? Results from our studies in juvenile primates show that succimer treatment is effective at accelerating the elimination of lead from the body, but chelation was only marginally better than the complete cessation of lead exposure alone. Studies in lead-exposed adult primates treated with a single 19-day course of succimer showed that chelation did not measurably reduce brain lead levels compared to vehicle-treated controls. A follow-up study in rodents that underwent one or two 21-day courses of succimer treatment showed that chelation significantly reduced brain lead levels, and that two courses of succimer were significantly more efficacious at reducing brain lead levels than one. In both the primate and rodent studies, reductions in blood lead levels were a relatively poor predictor of reductions in brain lead levels. Our studies in rodents demonstrated that it is possible for succimer chelation therapy to alleviate certain types of lead-induced behavioral/cognitive dysfunction, suggesting that if a succimer treatment protocol that produced a substantial reduction of brain lead levels could be identified for humans, a functional benefit might be derived. Finally, we also found that succimer treatment produced lasting adverse neurobehavioral effects when administered to non-lead-exposed rodents, highlighting the potential risks of administering succimer or other metal-chelating agents to children who do not have elevated tissue lead levels. It is of significant concern that this type of therapy has been advocated for treating autism.Keywords
This publication has 20 references indexed in Scilit:
- Succimer chelation normalizes reactivity to reward omission and errors in lead-exposed ratsNeurotoxicology and Teratology, 2007
- Succimer Chelation Improves Learning, Attention, and Arousal Regulation in Lead-Exposed Rats but Produces Lasting Cognitive Impairment in the Absence of Lead ExposureEnvironmental Health Perspectives, 2007
- Oral succimer decreases the gastrointestinal absorption of lead in juvenile monkeys.Environmental Health Perspectives, 2001
- The Effect of Chelation Therapy with Succimer on Neuropsychological Development in Children Exposed to LeadNew England Journal of Medicine, 2001
- Efficacy of Succimer Chelation for Reducing Brain Pb Levels in a Rodent ModelEnvironmental Research, 1998
- Metabolism of meso-2,3-dimercaptosuccinic acid in lead-poisoned children and normal adults.Environmental Health Perspectives, 1995
- Pharmacokinetics of meso-2,3- dimercaptosuccinic acid in patients with lead poisoning and in healthy adultsThe Journal of Pediatrics, 1994
- Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxicationThe Journal of Pediatrics, 1992
- MESO-2,3-Dimercaptosuccinic Acid: Chemical, Pharmacological and Toxicological Properties of an Orally Effective Metal Chelating AgentAnnual Review of Pharmacology and Toxicology, 1990
- Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrationsThe Journal of Pediatrics, 1988